- Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
- Revance Announces Proposed Public Offering of Common Stock
- Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update
- Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024
- Revance to Participate in Upcoming Investor Conferences
- Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®
- Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference
- Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook
More ▼
Key statistics
On Monday, Revance Therapeutics Inc (RVNC:NMQ) closed at 4.94, 1.23% above its 52-week low of 4.88, set on Mar 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.30 |
---|---|
High | 5.35 |
Low | 4.88 |
Bid | 4.90 |
Offer | 5.05 |
Previous close | 4.94 |
Average volume | 2.04m |
---|---|
Shares outstanding | 103.96m |
Free float | 79.61m |
P/E (TTM) | -- |
Market cap | 551.52m USD |
EPS (TTM) | -3.81 USD |
Data delayed at least 15 minutes, as of Mar 18 2024 20:00 BST.
More ▼